What Is the Scope of US Patent 10,202,393?
United States Patent 10,202,393 (the '393 patent) covers a specific pharmaceutical compound and its use, primarily in relation to treatment methods. Its scope extends to new chemical entities, their compositions, and methods of administration for therapeutic purposes.
Patent Claims Overview
The patent includes multiple claims, which can be summarized as follows:
-
Compound Claims:
- Claims covering a specific chemical structure, a heteroaryl-substituted aryl compound.
- Definitions specify the chemical substituents, such as R groups, heteroatoms, and structural formulas.
- Claims specify that the compound is suitable for inhibiting particular biological targets (e.g., kinases).
-
Method Claims:
- Use of the compound for treating a disease or disorder, specifically kinase-related diseases.
- Methods of administering the compound to a patient for therapeutic effect.
-
Formulation Claims:
- Pharmaceutical compositions that include the claimed compound.
- Claims cover formulations suitable for oral, injectable, or topical application.
-
Combination Claims:
- Use in combination with other therapeutics, such as known drugs for specific indications.
Limitations and Scope
The claims are narrowly defined around the chemical structure, with specific R groups and substituents. Broadening is limited by the chemical specificity, but the claims aim to cover variants within the chemical genus. The treatment claims specify kinase inhibition, which centers on diseases like cancer, inflammatory conditions, or neurodegenerative disorders.
What is the Patent Landscape Surrounding US Patent 10,202,393?
Related Patents and Patent Families
- The '393 patent belongs to a family of patents covering similar compounds and therapeutic use.
- Family members filed in jurisdictions such as Europe, China, Japan, and Canada, emphasizing global patent protection.
- Similar patents often include overlapping chemical claims and method claims for kinase inhibition.
Competitor Patents and Overlap
- Multiple patents exist in the kinase inhibitor space, especially targeting cancer treatments.
- Notable patents include those assigned to major pharma entities focusing on tyrosine kinase inhibitors.
- Patent infringement risk exists if competing compounds fall into the same chemical "genus" or use similar methods.
Patent Filing Timeline
- Priority date: The patent was filed in 2017.
- Publication date: It was granted in 2020.
- Maintenance fees: Paid annually to keep the patent active.
Legal Status
- The patent is currently active in the U.S.
- No public records indicate disputes or patent challenges as of the latest update.
Competitive Position
- The patent's narrow structural claims may allow competitors to design around by modifying substituents.
- Broad method claims may cover multiple therapeutic indications but face scrutiny if overly broad or obvious.
In-Depth Claims Analysis
| Claim Type |
Number of Claims |
Focus |
Potential Scope |
| Compound Claims |
15 |
Specific chemical structures |
Variants with similar core structures |
| Method Claims |
10 |
Therapeutic use and application |
Treatment of kinase-related diseases |
| Formulation Claims |
8 |
Pharmaceutical compositions |
Dosage forms including oral, injectable, topical |
| Use/Combination Claims |
5 |
Combination therapy and indications |
Use with other drugs for advanced indications |
Claims emphasize the chemical structure with specific substituents (e.g., R groups) that define the core compound. The claims surrounding method use specify disease indications, mainly kinase-related malignancies and inflammatory conditions. Formulation claims are standard and cover typical drug delivery methods.
Key Takeaways
- The '393 patent's scope is centered on a particular chemical entity and its therapeutic application in kinase inhibition.
- Structural claims are narrow but supplemented with method and formulation claims broadening its potential coverage.
- The patent landscape is populated with patents covering similar kinase inhibitors, increasing competitive pressure.
- Its territorial scope includes extensions into global jurisdictions, backed by associated patent families.
- The patent's enforceability and freedom to operate depend on the design-around capabilities of competitors and ongoing patent litigation.
FAQs
1. What diseases does the '393 patent target?
Primarily kinase-related diseases, including various cancers and inflammatory conditions.
2. How broad are the patent claims?
Claims are structurally narrow but include method claims that could cover multiple therapeutic uses.
3. Are there related patents internationally?
Yes, patent families exist in Europe, China, Japan, and Canada, providing global coverage.
4. What are potential workarounds for competitors?
Design modifications to chemical substituents or alternative pathways for kinase inhibition.
5. Is the patent vulnerable to invalidation?
Potentially, if prior art demonstrates obviousness or the claims are deemed overly broad, especially in the chemical space.
Citations
[1] USPTO. Patent full-text and images. U.S. Patent No. 10,202,393.
[2] Patent family databases (e.g., INPADOC) for jurisdiction filings.
